Alzheimer's disease (AD) remains a significant global health challenge, highlighting the need for novel dual inhibitors targeting acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.